Podium to Practice: ASH® 2025 – LEUKEMIA: VICEROY Study

Podium to Practice: ASH® 2025 – LEUKEMIA: VICEROY Study

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Speakers

Dr. Lynn Savoie

Dr. Brian Leber

Studies / Trials Discussed

ID 654 – Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

This program has been made possible through unrestricted support from Astellas and Daiichi Sankyo.

Studies/trials discussed:

ID 654 – Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study
Tagged